Statement of Changes in Beneficial Ownership (4)
December 02 2020 - 3:10PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
RYAN ARTHUR F |
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC.
[
REGN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
777 OLD SAW MILL RIVER ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/1/2020 |
(Street)
TARRYTOWN, NY 10591
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 12/1/2020 | | S(1) | | 2 | D | $515.64 (2) | 23741 | D | |
Common Stock | 12/1/2020 | | S(1) | | 4 | D | $516.37 (3) | 23737 | D | |
Common Stock | 12/1/2020 | | S(1) | | 11 | D | $517.63 (4) | 23726 | D | |
Common Stock | 12/1/2020 | | S(1) | | 6 | D | $518.55 (5) | 23720 | D | |
Common Stock | 12/1/2020 | | S(1) | | 13 | D | $519.6 (6) | 23707 | D | |
Common Stock | 12/1/2020 | | S(1) | | 27 | D | $520.58 (7) | 23680 | D | |
Common Stock | 12/1/2020 | | S(1) | | 10 | D | $521.5 (8) | 23670 | D | |
Common Stock | 12/1/2020 | | S(1) | | 14 | D | $522.45 (9) | 23656 | D | |
Common Stock | 12/1/2020 | | S(1) | | 10 | D | $523.32 (10) | 23646 | D | |
Common Stock | 12/1/2020 | | S(1) | | 3 | D | $524.31 (11) | 23643 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). |
(2) | Represents volume-weighted average price of sales of 2 shares of Company stock on December 1, 2020 at prices ranging from $515.55 to $515.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. |
(3) | Represents volume-weighted average price of sales of 4 shares of Company stock on December 1, 2020 at prices ranging from $516.00 to $516.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. |
(4) | Represents volume-weighted average price of sales of 11 shares of Company stock on December 1, 2020 at prices ranging from $517.03 to $517.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. |
(5) | Represents volume-weighted average price of sales of 6 shares of Company stock on December 1, 2020 at prices ranging from $518.10 to $518.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. |
(6) | Represents volume-weighted average price of sales of 13 shares of Company stock on December 1, 2020 at prices ranging from $519.30 to $519.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. |
(7) | Represents volume-weighted average price of sales of 27 shares of Company stock on December 1, 2020 at prices ranging from $520.14 to $520.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. |
(8) | Represents volume-weighted average price of sales of 10 shares of Company stock on December 1, 2020 at prices ranging from $521.04 to $521.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. |
(9) | Represents volume-weighted average price of sales of 14 shares of Company stock on December 1, 2020 at prices ranging from $522.00 to $522.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. |
(10) | Represents volume-weighted average price of sales of 10 shares of Company stock on December 1, 2020 at prices ranging from $523.03 to $523.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. |
(11) | Represents volume-weighted average price of sales of 3 shares of Company stock on December 1, 2020 at prices ranging from $524.00 to $524.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
RYAN ARTHUR F 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 | X |
|
|
|
Signatures
|
/s/**Arthur F. Ryan | | 12/2/2020 |
**Signature of Reporting Person | Date |
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024